This article endeavors to navigate the clinical journey of bispecific antibodies (BsAbs), from
elucidating common toxicities and management strategies to examining novel agents and …

Bispecific antibodies (bsAbs) are an emerging therapy in the treatment of large B-cell
lymphomas (LBCLs). There is a gap in the research on the safety and efficacy of bsAbs in …

B-cell non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy, capable
of invading the brain, meninges, and nerve roots of the brain and spine, leading to high …

Background B-cell non-Hodgkin lymphoma (B-NHL) is the most common type of lymphoma
and is significantly heterogeneous among various subtypes. Despite of considerable …

Backgroud: The introduction of highly active immunotherapies has changed the outcome of
B-cell non-Hodgkin lymphomas (B-NHLs) in the last two decades. Since then, important …

Introduction Since the approval of the bispecific antibody blinatumomab in 2017 for the
treatment of acute lymphoblastic leukemia in relapse, the development of numerous …

Despite the great advancements in treatment strategies for hematological malignancies
(HMs) over the years, their effective treatment remains challenging. Conventional treatment …

Background Studies have indicated an association between gut microbiota (GM) and non-
Hodgkin lymphoma (NHL). However, the causality between GM and NHL remains unclear …

Diffuse large B-cell lymphoma (DLBCL) is a malignancy of immense biological and clinical
heterogeneity. Based on the transcriptomic or genomic approach, several different …

In human leukocyte antigen (HLA)-mismatched allogeneic stem cell transplantation settings,
donor-specific anti-HLA antibodies (DSAs) can independently lead to graft failure, including …